Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 October 2017Website:
http://rhythmtx.comNext earnings report:
05 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:19:46 GMTDividend
Analysts recommendations
Institutional Ownership
RYTM Latest News
BOSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on October 4, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 30,050 shares of its common stock to nine new employees.
IMCIVREE is FDA-approved for obesity due to genetic mutations and aims to expand its label to include children as young as 2 years old. The company is also exploring IMCIVREE for hypothalamic obesity in a phase 3 study, with data expected in the 1st half of 2025. Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months.
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on September 11, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,450 shares of its common stock to four new employees.
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency -- -- FDA sets PDUFA goal date of December 26, 2024 --
BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on August 8, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 16,200 shares of its common stock to five new employees.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants David Connolly - IR & Corporate Communications David Meeker - Chairman, CEO & President Jennifer Lee - EVP & Head, North America Hunter Smith - CFO Yann Mazabraud - EVP & Head, International Conference Call Participants Jeff Hung - Morgan Stanley Phil Nadeau - TD Cowen Whitney Ijem - Canaccord Genuity Dae Gon Ha - Stifel Corinne Johnson - Goldman Sachs Tazeen Ahmad - BofA Securities Joseph Stringer - Needham & Company Michael Higgins - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Second Quarter 2024 Earnings Conference Call.
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.82 per share a year ago.
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization for IMCIVREE® (setmelanotide) include children between 2 and younger than 6 years old with obesity due to Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. “We continue to work closely with health authorities throughout the European Union to make IMCIVREE available to eligible patients with uncontrolled hunger and early-onset, severe obesity associated with these rare neuroendocrine diseases,” said Yann Mazabraud, Executive Vice President, Head of International at Rhythm Pharmaceuticals.
- 1(current)
What type of business is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic agents for the treatment of rare genetic disorders characterized by severe obesity and unrelenting hunger or hyperphagia. The company was founded in 2013 in Boston, Massachusetts. The company's research is dedicated to studying rare genetic obesity disorders caused by a disruption in the pathway in the brain known as the melanocortin-4 receptor (MC4R) pathway. The company produces an MC4R agonist - setmelanotide, the use of which may serve as a replacement therapy for the treatment of MC4R pathway deficiency. The company also has a number of drugs in early stages of research. Currently, the company does not have any approved drugs.
What sector is Rhythm Pharmaceuticals in?
Rhythm Pharmaceuticals is in the Healthcare sector
What industry is Rhythm Pharmaceuticals in?
Rhythm Pharmaceuticals is in the Biotechnology industry
What country is Rhythm Pharmaceuticals from?
Rhythm Pharmaceuticals is headquartered in United States
When did Rhythm Pharmaceuticals go public?
Rhythm Pharmaceuticals initial public offering (IPO) was on 09 October 2017
What is Rhythm Pharmaceuticals website?
https://rhythmtx.com
Is Rhythm Pharmaceuticals in the S&P 500?
No, Rhythm Pharmaceuticals is not included in the S&P 500 index
Is Rhythm Pharmaceuticals in the NASDAQ 100?
No, Rhythm Pharmaceuticals is not included in the NASDAQ 100 index
Is Rhythm Pharmaceuticals in the Dow Jones?
No, Rhythm Pharmaceuticals is not included in the Dow Jones index
When was Rhythm Pharmaceuticals the previous earnings report?
No data
When does Rhythm Pharmaceuticals earnings report?
The next expected earnings date for Rhythm Pharmaceuticals is 05 November 2024